The PANSS is currently the most established scale in patients with schizophrenia. For example in the high impact journal "Schizophrenia Bulletin" Kay's publication on the Positive and Negative ...
Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with schizophrenia, long-term results from the phase III EMERGENT-4 trial showed.
Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results